<DOC>
	<DOCNO>NCT00332553</DOCNO>
	<brief_summary>This pilot study design explore effect combine treatment raloxifene HCl 60 mg oral 17 beta-estradiol 1mg/day number vasomotor episode ( hot flash plus night sweat ) postmenopausal woman discontinue continuous combine hormone replacement therapy ( ccHRT ) compare woman treat raloxifene HCl 60 mg alone .</brief_summary>
	<brief_title>Study Hot Flashes Night Sweats Postmenopausal Women Receiving Combination Raloxifene Oral Estrogen</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Post menopausal woman , 5070 year age Had take ccHRT least 6 month prior study entry No unexplained vaginal bleed 3 month prior study entry Understand sign inform consent document Prior hysterectomy Endometrial thickness ( exclude endometrial fluid ) great 8 mm endometrial fluid great equal 4 mm study entry Abnormal Pap smear study screen within precede 3 year Abnormal transvaginal ultrasound result study screen Past current history malignant neoplasm</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>